Ayala Pharmaceuticals Inc (ADXS)

[mypekeispooped]

Was it this? "And finally, in our prostate cancer franchise, we anticipated a preliminary data readout of both Part B monotherapy and checkpoint combination data for ADXS-PSA. The immunotherapy landscape continues to evolve with promising technology advancements such as checkpoint inhibitors and most recently CAR-T therapy.

However, there are still significant unmet needs which we feel that the Lm Technology can address, specifically Lm Technology has the potential to enhance the treatments in combination as having generally well tolerated safety profile and does not generate neutralizing antibodies."